LAWRENCEVILLE, N.J. - IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage biotechnology company, has announced positive outcomes from a recent study conducted by the Wistar Institute on its vaccine candidate, IMNN-101, against the SARS-CoV-2 variant XBB.1.5.
The study, which is part of the company's preparation for a Phase 1 trial set to commence in the second quarter, demonstrated the vaccine's immunogenicity and protective activity in a mouse model.
The Wistar Institute's findings revealed that a single dose of IMNN-101 generated significant IgG neutralizing antibody and T-cell responses. The vaccine's efficacy was further supported by the complete protection observed in mice challenged with the live virus 21 days after receiving a second vaccination.
These results build on previous data indicating that IMNN-101 could offer comparable or even superior protection against SARS-CoV-2 compared to commercial mRNA vaccines, with the added advantages of stability at refrigerated temperatures and sustained immune response for up to four months post-vaccination.
IMUNON's PlaCCine vaccine modality, which IMNN-101 is based on, utilizes a synthetic DNA delivery system administered via intramuscular injection. This technology is part of IMUNON's broader strategy to develop non-viral DNA-mediated immunotherapies and next-generation vaccines.
The company's portfolio includes various modalities targeting solid tumors, infectious diseases, and personalized cancer vaccines.
The announcement of these findings comes as the XBB.1.5 variant has been designated a variant of concern for the 2023-2024 season by the U.S. Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee.
IMUNON's approach, leveraging its PlaCCine technology, appears to offer a promising alternative to mRNA vaccines, particularly in terms of storage and durability.
IMUNON's lead clinical program, IMNN-001, is currently in Phase 2 development for the treatment of advanced ovarian cancer. The company is also engaged in preclinical studies for a COVID-19 booster vaccine and treatments for other diseases, including the LASSA virus.
The information reported is based on a press release statement from IMUNON, Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.